The risk of urinary tract infections in patients with psoriasis on systemic medications in biobadaderm registry: a prospective cohort study

Sahuquillo-Torralba, Antonio; Ferran Farrés, Marta; García-Doval, Ignacio; Biobadaderm Study Group

doi:http://dx.doi.org/10.1016/j.jaad.2019.07.028

The risk of urinary tract infections in patients with psoriasis on systemic medications in biobadaderm registry: a prospective cohort study

Citation

Sahuquillo-Torralba A, Carretero G, Rivera R, Ferrándiz C, Daudén-Tello E, de la Cueva P, et al. The risk of urinary tract infections in patients with psoriasis on systemic medications in biobadaderm registry: a prospective cohort study. J Am Acad Dermatol. 2020 Mar; 82(3):738-41. DOI: 10.1016/j.jaad.2019.07.028

Abstract

Biobadaderm is a multicenter prospective cohort that was created to evaluate the safety of systemic therapy for psoriasis patients.2 Once a year, reports are created. In 2018, a signal regarding symptomatic urinary tract infection (UTI) was detected.